Oborska, IT

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

Kullberg, B., Sobel, J., Ruhnke, M., Pappas, P., Viscoli, C., Rex, J., Cleary, J., Rubinstein, E., Church, L., Brown, J., et al. (2005) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 521

Ocular manifestations of candidemia

Oude Lashof, A. M. L., Rothova, A., Sobel, J. D., Ruhnke, M., Pappas, P. G., Viscoli, C., Schlamm, H. T., Oborska, I. T., Rex, J. H., & Kullberg, B. J. (2011) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityOcular Infections and Treatments

Cited by 218

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial

Pappas, P., Kullberg, B. J., Vazquez, J. A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., Ben-Ami, R., Ferrer, R., McCarty, T. P., et al. (2020) · Open Forum Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 17